NCT00044902已完成2 期
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Amgen
研究概览
简要总结
Epratuzumab is currently being studied in combination with rituximab, for the treatment of patients with low-grade NHL who failed previous chemotherapy and have never received rituximab or who received rituximab as a single agent or in combination with chemotherapy as their last treatment and who demonstrated a partial response or complete response for at least 12 months.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of relapsed or refractory low-grade, CD20+, B-cell NHL * Received and failed at least 1 prior regimen of chemotherapy * Rituximab-naive or received prior rituximab in their last treatment (single agent or in combination with chemotherapy) and demonstrated a time to progression of at least 12 months.
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell LymphomaLymphomaNCT00070447National Cancer Institute (NCI)
进行中（未招募）
2 期
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNSquamous Cell Carcinoma of the Head and NeckNCT03341936Dana-Farber Cancer Institute29
已完成
2 期
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's LymphomaLymphomaNCT00274924Eastern Cooperative Oncology Group100
已完成
2 期
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaLymphomaNCT00301821Alliance for Clinical Trials in Oncology107
终止
2 期
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated MesotheliomaMesothelioma, MalignantNCT03502746Arkadiusz Z. Dudek, MD34